In patients with untreated, advanced melanoma, the combination of immune checkpoint inhibitors relatlimab and Opdivo (nivolumab) doubled the progression-free survival benefit compared to Opdivo alone, with a manageable safety profile, according to results of the phase II/III RELATIVITY-047 clinical trial reported by The University of Texas MD Anderson Cancer Center.
Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have built and demonstrated the potential efficacy of a new chimeric antigen receptor T-cell-based immunotherapy specifically designed to treat patients with cutaneous and rare subtypes of melanoma.
